GlassScriptPhysician profile
Lesa Kelly
NPI 1265598015
$261.01
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $55.41 · 2021: $58.90 · 2022: $20.00.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $83.98 | 2019-2020 | |
| Genentech USA, INC. | $30.89 | 2019-2022 | |
| Pfizer INC. | $28.53 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $25.25 | 2021 | |
| Genzyme Corporation | $23.11 | 2019 | |
| Avanir Pharmaceuticals, INC. | $21.86 | 2019 | |
| Merck Sharp & Dohme LLC | $18.47 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $15.18 | 2021 | |
| Novo Nordisk INC | $13.74 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lesa Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.